Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration

EuroIntervention

Volumn 11, Issue 11, 2016, Pages e1222-e1230

  Costa, Francesco ^a   Adamo, Marianna ^a   Ariotti, Sara ^a   Ferrante, Giuseppe ^b   Navarese, Eliano Pio ^c   Leonardi, Sergio ^d   Garcia Garcia, Hector ^e   Vranckx, Pascal ^f   Valgimigli, Marco ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e CARDIALYSIS   (Netherlands)

^f Hartcentrum Hasselt   (Belgium)

Author keywords

Acute coronary syndrome; Clopidogrel; Dual antiplatelet therapy (DAPT); Left main coronary artery; Proximal left anterior descending coronary artery; Stent thrombosis

Indexed keywords

CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGED; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; CORONARY STENT; CORONARY STENTING; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DRUG EFFECTS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK; TIME FACTOR;

AGED; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RISK; TICLOPIDINE; TIME FACTORS;

EID: 84962464471     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY15M08_04     Document Type: Article

References (18)

1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-70.
2. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-66.
3. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618.
4. Valgimigli M, Costa F, Byrne R, Haude M, Baumbach A, Windecker S. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention. 2015;11:68-74.
5. Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? Eur Heart J. 2015;36:1219-22.
6. Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, Zuffi A, Colombo F, Kubbajeh M, Parrinello G, Ferrari R. Randomized comparison of 6-versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dualantiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am Heart J. 2010;160:804-11.
7. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015-26.
8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
9. Cutlip DE, Nakazawa G, Krucoff MW, Vorpahl M, Mehran R, Finn AV, Vranckx P, Kimmelstiel C, Berger C, Petersen JL, Palabrica T, Virmani R. Autopsy validation study of the academic research consortium stent thrombosis definition. JACC Cardiovasc Interv. 2011;4:554-9.
10. Leaman DM, Brower RW, Meester GT, Serruys P, van den Brand M. Coronary artery atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular function. Circulation. 1981;63:285-99.
11. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17.
12. Valgimigli M, Rodriguez-Granillo GA, Garcia-Garcia HM, Malagutti P, Regar E, de Jaegere P, de Feyter P, Serruys PW. Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans. Eur Heart J. 2006;27:655-63.
13. Valgimigli M, Rodriguez-Granillo GA, Garcia-Garcia HM, Vaina S, De Jaegere P, De Feyter P, Serruys PW. Plaque composition in the left main stem mimics the distal but not the proximal tract of the left coronary artery: influence of clinical presentation, length of the left main trunk, lipid profile, and systemic levels of C-reactive protein. J Am Coll Cardiol. 2007;49:23-31.
14. Tian J, Dauerman H, Toma C, Samady H, Itoh T, Kuramitsu S, Domei T, Jia H, Vergallo R, Soeda T, Hu S, Minami Y, Lee H, Yu B, Jang IK. Prevalence and characteristics of TCFA and degree of coronary artery stenosis: an OCT, IVUS, and angiographic study. J Am Coll Cardiol. 2014;64:672-80.
15. Garcia-Garcia HM, Jang IK, Serruys PW, Kovacic JC, Narula J, Fayad ZA. Imaging plaques to predict and better manage patients with acute coronary events. Circ Res. 2014;114:1904-17.
16. Campos CM, Costa F, Garcia-Garcia HM, Bourantas C, Suwannasom P, Valgimigli M, Morel MA, Windecker S, Serruys PW. Anatomic characteristics and clinical implications of angiographic coronary thrombus: insights from a patient-level pooled analysis of SYNTAX, RESOLUTE, and LEADERS Trials. Circ Cardiovasc Interv. 2015;8. pii: e002279. doi: 10.1161/CIRCINTERVENTIONS.114.002279.
17. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35.
18. Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G, Calabro P, Oreto G, Zijlstra F, Valgimigli M. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. Eur Heart J. 2015;36:1242-51.